Zhejiang Jingxin Pharmaceutical Co., Ltd.
002020.SZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$10.22B
Close$
$21.52
81.3% upside
Current Fair Value
81.3% upsideUndervalued by 81.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $10.22 Billion |
|---|---|
| Enterprise Value | $10.21 Billion |
| Dividend Yield | $0.35 (2.95%) |
| Earnings per Share | $0.92 |
| Beta | -0.17 |
| Outstanding Shares | 820,881,245 |
Return
| Return on Equity | 12.03% |
|---|---|
| Return on Assets | 9.07% |
| Return on Invested Capital | 12.79% |
Valuation & Multiples
| P/E Ratio | 13.49 |
|---|---|
| PEG | -79.37 |
| Price to Sales | 2.97 |
| Price to Book Ratio | 1.7 |
| Enterprise Value to Revenue | 2.53 |
| Enterprise Value to EBIT | 12.5 |
| Enterprise Value to Net Income | 14 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.08 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 26, 2026
EPS Estimate
$0.27
Average shareholder expectationRevenue Estimate
$1.14 B
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$0.22
Average shareholder expectationRevenue Estimate
$1.11 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Zhejiang Jingxin Pharmaceutical Co., Ltd.
3,732 employees
CEO: Gang Lü Zhejiang Jingxin Pharmaceutical Co., Ltd. is a Chinese enterprise engaged in the full spectrum of pharmaceutical activities, from research and development to manufacturing and sales within the country. Its diverse product line includes a...